EC Number   |
Natural Substrates |
|---|
    1.4.3.4 | 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2 |
1-methyl-4-phenylpyridinium is the ultimate product |
| 1.4.3.4 | 2 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + 2 H2O + 3 O2 |
activation of the neurotoxin to neurotoxic pyridinium cations. MPTP easily crosses the blood-brain barrier and is preferentially metabolized by MAO-B present in glial cells to 1-methyl-4-phenyl-2,3-dihydropyridinium. This enzymatic metabolite is subsequently oxidized to 1-methyl-4-phenylpyridinium, which is selectively uptaken by dopaminergic cells, producing inhibition of complex I of mitochondria, energy depletion, oxidative stress and cell death |
| 1.4.3.4 | 2-phenylethylamine + H2O + O2 |
- |
| 1.4.3.4 | 4-dimethylaminophenylethylamine + H2O + O2 |
substrate of MAO-B |
| 1.4.3.4 | 4-tyramine + H2O + O2 |
in vivo activity, overview |
| 1.4.3.4 | 5-hydroxytryptamine + H2O + O2 |
- |
| 1.4.3.4 | 5-methoxy-N,N-dimethyltryptamine + H2O + O2 |
i.e. 5-MeO-DMT, a psychoactive indolealkylamine drug found in a variety of plant preparations, e.g. Virola snuffs and Ayahuasca, and venom of psychoactive toads, e.g. Colorado River Bufo alvarius. 5-MeO-DMT is known as a nonselective 5-HT receptor agonist. MAO-A eliminates the drug 5-MeO-DMT through oxidative deamination |
| 1.4.3.4 | benzylamine + H2O + O2 |
- |
| 1.4.3.4 | benzylamine + H2O + O2 |
MAO-A |
| 1.4.3.4 | dopamine + H2O + O2 |
- |
